Nakajima R, Ishida Y, Yamaguchi F, Otani T, Ono Y, Nomura M, Une T, Osada Y
Research Institute, Daiichi Seiyaku Co., Ltd., Tokyo, Japan.
Arzneimittelforschung. 1988 Jul;38(7A):986-92.
Subcutaneous injection of N2-[N-acetylmuramoyl)-L-alanyl-D-isoglutaminyl]-N6-stearoyl-L-lysine (MDP-Lys(L18), muroctasin), a synthetic muramyl dipeptide derivative, favoured recovery of mice from experimental leukopenia induced by cyclophosphamide or by irradiation with X-rays. These effects were observed only when MDP-Lys(L18) treatment occurred after cyclophosphamide injection or X-ray irradiation. Prophylactic treatment resulted in neither preventive nor restorative efficacy on leukopenia. In contrast, glutathione was hardly effective on leukopenia in both models, irrespective of treatment timing. The restorative efficacy of muroctasin was found to be dose-dependent and to be attributable at least to its augmenting effect on colony-stimulating factor production, followed by the marked proliferation and differentiation of myeloblasts towards mature granulocytes in the bone marrow. These beneficial effects of MDP-Lys(L18) warrant further evaluation of its clinical usefulness.
皮下注射N2-［N-乙酰胞壁酰-L-丙氨酰-D-异谷氨酰胺基］-N6-硬脂酰-L-赖氨酸（MDP-Lys(L18)，胞壁酰三肽），一种合成的胞壁酰二肽衍生物，有利于小鼠从环磷酰胺或X射线照射诱导的实验性白细胞减少症中恢复。这些效果只有在环磷酰胺注射或X射线照射后进行MDP-Lys(L18)治疗时才会观察到。预防性治疗对白细胞减少症既无预防作用也无恢复作用。相比之下，无论治疗时机如何，谷胱甘肽在两种模型中对白细胞减少症几乎都没有效果。发现胞壁酰三肽的恢复功效具有剂量依赖性，并且至少可归因于其对集落刺激因子产生的增强作用，随后骨髓中的成髓细胞向成熟粒细胞显著增殖和分化。MDP-Lys(L18)的这些有益作用值得进一步评估其临床实用性。
